



# **King's Research Portal**

DOI: 10.1038/s41380-019-0450-0

Document Version Peer reviewed version

Link to publication record in King's Research Portal

Citation for published version (APA):

Villalon-Reina, J. E., Martínez, K., Qu, X., Ching, C. R. K., Nir, T., Kothapalli, D., Corbin, C., Sun, D., Lin, A., Forsyth, J. K., Kushan, L., Vajdi, A., Jalbrzikowski, M., Hansen, L., Jonas, R. K., Van Amelsvoort, T., Bakker, G., Kates, W. R., Antshel, K. M., ... Bearden, C. E. (2019). Altered white matter microstructure in 22q11.2 deletion syndrome: a multisite diffusion tensor imaging study. *Molecular Psychiatry*. https://doi.org/10.1038/s41380-019-0450-0

#### Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

#### General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal

#### Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

# Altered White Matter Microstructure in 22q11.2 Deletion Syndrome: A Multi-Site Diffusion Tensor Imaging Study

# Running Title: DTI in 22q11.2 Deletion Syndrome

Julio E. Villalón-Reina<sup>1</sup>, Kenia Martínez<sup>2</sup>, Xiaoping Qu<sup>1</sup>, Christopher Ching<sup>1,3</sup>, Talia M. Nir<sup>1</sup>, Deydeep Kothapalli<sup>1</sup>, Conor Corbin<sup>1</sup>, Daqiang Sun<sup>3,4</sup>, Amy Lin<sup>3</sup>, Jennifer K. Forsyth<sup>3,5</sup>, Leila Kushan<sup>3</sup>, Ariana Vajdi<sup>3</sup>, Maria Jalbrzikowski<sup>6</sup>, Laura Hansen<sup>3</sup>, Rachel K. Jonas<sup>3</sup>, Therese van Amelsvoort<sup>8</sup>, Geor Bakker<sup>8</sup>, Wendy R. Kates<sup>9</sup>, Kevin M. Antshel<sup>10</sup>, Wanda Fremont<sup>9</sup>, Linda E. Campbell<sup>11</sup>, Kathryn L. McCabe<sup>12</sup>, Eileen Daly<sup>13</sup>, Maria Gudbrandsen<sup>13</sup>, Clodagh Murphy<sup>13</sup>, Declan Murphy<sup>13</sup>, Michael Craig<sup>14</sup>, Beverly Emanuel<sup>15</sup>, Donna McDonald-McGinn<sup>15</sup>, Jacob Vorstman<sup>16</sup>, Ania Fiksinski<sup>16</sup>, Sanne Koops<sup>16</sup>, Kosha Ruparel<sup>17</sup>, David Roalf<sup>17</sup>, Raquel E. Gur<sup>18</sup>, J. Eric Schmitt<sup>19</sup>, Tony J. Simon<sup>20</sup>, Naomi J. Goodrich-Hunsaker<sup>20,21</sup>, Courtney A. Durdle<sup>20</sup>, Joanne Doherty<sup>22,23</sup>, Adam C. Cunningham<sup>22</sup>, Marianne van den Bree<sup>22</sup>, David E. J. Linden<sup>22,23</sup>, Michael Owen<sup>22</sup>, Hayley Moss<sup>22</sup>, Sinead Kelly<sup>24</sup>, Gary Donohoe<sup>25</sup>, Kieran C. Murphy<sup>26</sup>, Celso Arango<sup>2</sup>, Neda Jahanshad<sup>1,\*</sup>, Paul M. Thompson<sup>1,7,\*</sup>, Carrie E. Bearden<sup>3,5,\*</sup>

1 Imaging Genetics Center, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA, USA 2 Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Madrid, Spain: Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Universidad Europea de Madrid, Madrid, Spain 3 Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles, Los Angeles, CA, USA 4 Department of Mental Health, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA 5 Department of Psychology, University of California at Los Angeles, Los Angeles, CA USA 6 Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA 7 Departments of Neurology, Psychiatry, Radiology, Engineering, Pediatrics and Ophthalmology, University of Southern California, CA, USA 8 Department of Psychiatry & Neuropsychology, Maastricht University, Netherlands 9 Department of Psychiatry and Behavioral Sciences, State University of New York, Upstate Medical University, NY, USA 10 Department of Psychology, Syracuse University, Syracuse, NY, USA 11 Priority Research Centre GrowUpWell, University of Newcastle, Australia; School of Psychology, University of Newcastle, Australia 12 School of Psychology, University of Newcastle, Australia; UC Davis MIND Institute and

**12** School of Psychology, University of Newcastle, Australia; UC Davis MIND Institute and Department of Psychiatry and Behavioral Sciences

**13** Sackler Institute for Translational Neurodevelopment and Department of Forensic and Neurodevelopmental Sciences, King's College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK

**14** Sackler Institute for Translational Neurodevelopment and Department of Forensic and Neurodevelopmental Sciences, King's College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK & National Autism Unit, Bethlem Royal Hospital, UK

**15** Division of Human Genetics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

**16** Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands

17 Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

**18** Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, PA, USA

**19** Departments of Radiology and Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

20 UC Davis MIND Institute and Department of Psychiatry and Behavioral Sciences, CA, USA21 Brigham Young University, UT, USA

**22** MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, Wales, UK

**23** The Cardiff University Brain Research Imaging Centre (CUBRIC), Cardiff University, Cardiff, Wales, UK

**24** Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, MA, USA

**25** Centre for Neuroimaging and Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, National University of Ireland Galway, Galway, Ireland

26 Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland.

\*To whom correspondence should be addressed. UCLA Semel Institute for Neuroscience and Human Behavior, 760 Westwood Plaza, Rm A7-460, Los Angeles, CA 90095, USA. Email: CBearden@mednet.ucla.edu; tel: (310) 206-2983.

# Journal: Molecular Psychiatry

Number of Figures (main text): 4 Number of Tables (main text): 1 References: 75 Supplementary Data: 7 figures, 20 tables

# Abstract

22q11.2 deletion syndrome (22q11DS) - a neurodevelopmental condition caused by a hemizygous deletion on chromosome 22 - is associated with an elevated risk of psychosis and other developmental brain disorders. Prior single-site diffusion magnetic resonance imaging (dMRI) studies have reported altered white matter (WM) microstructure in 22q11DS, but small samples and variable methods have led to contradictory results. Here we present the largest study ever conducted of dMRI-derived measures of WM microstructure in 22q11DS (334 22q11.2 deletion carriers and 260 healthy age- and sex-matched controls; age range 6-52 years). Using harmonization protocols developed by the ENIGMA-DTI working group, we

identified widespread reductions in mean, axial and radial diffusivities in 22q11DS, most pronounced in regions with major cortico-cortical and cortico-thalamic fibers: the corona radiata, corpus callosum, superior longitudinal fasciculus, posterior thalamic radiations and sagittal stratum (Cohen's *d*'s ranging from -0.9 to -1.3). Only the posterior limb of the internal capsule (IC), comprised primarily of corticofugal fibers, showed higher axial diffusivity in 22q11DS. 22q11DS patients showed higher mean fractional anisotropy (FA) in callosal and projection fibers (IC and corona radiata) relative to controls, but lower FA than controls in regions with predominantly association fibers. Psychotic illness in 22q11DS was associated with more substantial diffusivity reductions in multiple regions. Overall, these findings indicate large effects of the 22q11.2 deletion on WM microstructure, especially in major cortico-cortical connections. Taken together with findings from animal models, this pattern of abnormalities may reflect disrupted neurogenesis of projection neurons in outer cortical layers.

#### 1. Introduction

22q11.2 deletion syndrome (22q11DS; also known as Velocardiofacial or DiGeorge syndrome) results from a recurrent 1.5-3 megabase (Mb) microdeletion on the long arm of chromosome 22. It is the most common chromosomal microdeletion syndrome, with a prevalence of 1 per 3000 to 4000 live births<sup>1,2</sup>. 22q11DS is associated with a range of characteristic abnormalities, including cardiac defects, craniofacial anomalies, and intellectual disability<sup>1,3</sup>. Particularly, it increases the risk for psychotic illness around 25-fold relative to the general population<sup>2,4–6</sup>. The deletion is also associated with elevated rates of other developmental neuropsychiatric disorders<sup>5</sup>, but the increased risk for psychosis in 22q11DS may be the most specific association, as it greatly exceeds the roughly 3-fold increased risk of psychosis associated with general developmental delay<sup>7,8</sup>. Notably, mouse models of the 22q11.2 deletion show fewer neural progenitors of projection neurons in cortical layers 2/3, which leads to altered connectivity between cortical association areas<sup>9</sup>. Hence, 22q11DS is a compelling model to study genetic causes and neural mechanisms underlying disorders of cortical circuit development such as schizophrenia.

WM microstructural properties can be quantified non-invasively in humans using dMRI. Fractional anisotropy (FA), a widely used measure of WM microstructural organization, is derived from a common dMRI reconstruction method, diffusion tensor imaging (DTI), and may reflect the coherence and density of fiber tracts in a voxel. Other DTI indices, axial diffusivity (AD) and radial diffusivity (RD), are also altered in a range of brain diseases<sup>10</sup>. For example, lower AD can reflect axonal damage and degeneration<sup>11</sup>, or reduced axonal diameter<sup>12</sup>. RD is associated with inter-axonal spacing (i.e., extracellular space)<sup>12</sup>; animal models, demyelination and dysmyelination can lead to abnormally high RD<sup>13–15</sup>. Mean diffusivity (MD), an average of radial and axial diffusivities, is a generalized measure of the surface-to-volume ratio of cellular membranes<sup>16</sup>.

Disturbances in WM microstructural organization have been frequently reported in 22q11DS; however, studies to date have been relatively small, with highly variable findings. While many studies reported lower FA in 22q11DS compared to healthy controls (HC) in major WM tracts, including commissural, association and projection fibers<sup>17–22</sup>, several others reported higher overall FA<sup>23–25</sup>, or mixed findings across tracts<sup>26–31</sup>. Most studies reported consistent decreases in DTI-derived diffusivity measures (i.e., MD, RD, and AD), although some report mixed results<sup>20</sup> or higher WM diffusivity in 22q11DS<sup>21,22</sup>. **Supplementary Table S1** summarizes prior findings. These contrasting reports have hindered conclusions regarding the nature of WM microstructural abnormalities in 22q11DS.

Contrasting findings in prior studies may also be due to different analytical techniques, ranging from tract-based spatial statistics (TBSS<sup>32</sup>) to voxel-wise analyses and tractometry. This technical variability makes it difficult to apply traditional meta-analytic approaches that attempt to combine summary statistics from prior publications.

WM differences associated with psychosis are of interest in 22q11DS. Psychotic symptoms in 22q11DS have been associated with higher FA and lower WM diffusivities, but not always in the same regions across studies<sup>22,25,30,31,33,34</sup>. Additionally, there is variability in deletion breakpoints; 85-90% of individuals with the deletion have a ~3 Mb (A-D) deletion, containing 46 protein-coding genes, whereas ~10% of cases have a nested 1.5 Mb (A-B) deletion<sup>1</sup>. WM differences in 22q11DS may be due in part to variable deletion size, as deletion size impacts cortical surface area<sup>35</sup>.

To address these uncertainties and determine factors that affect WM abnormalities in 22q11DS, the 22q11DS Working Group of the Enhancing Neuroimaging Genetics through Meta-analysis Consortium (ENIGMA-22q11DS) performed a coordinated analysis of the raw dMRI data from ten independent studies, and meta-analyzed group differences and their modulators. We addressed these questions:

(1) Are there consistent group differences in WM microstructure between 22q11.2 deletion carriers and demographically-matched healthy controls?

(2) Are there differential age effects between groups, suggesting altered WM development in 22q11DS?

(3) Do 22q11DS participants with a psychotic disorder show more severe WM alterations, and do these differences overlap with those found in idiopathic schizophrenia?

- (4) Does deletion size impact DTI indices?
- (5) Is WM microstructure related to cognitive abilities, in 22q11DS and in HC?

#### 2.Methods

#### 2.1. Participants

dMRI data were contributed from ten studies previously acquired by the ENIGMA-22q11DS working group. This analysis included 594 participants: 334 with 22q11DS (mean age: 16.88 ± 6.43, 153 females) and 260 healthy controls (HC; mean age: 16.55 ± 8.01, 123 females). Demographic characteristics are shown in **Table 1** and **Supplemental Table S2a-S2b**. Psychotropic medication status at the time of scanning is included in **Supplementary Table S2c**. Individual study details are in **Supplemental Table S3**. Institutional review boards at participating institutions approved all study procedures, and material transfer agreements approved any sharing of de-identified imaging data. Written informed consent was obtained from all study participants or a legal guardian.

#### 2.2. Measurements of sample-specific phenotype characteristics

All sites conducted structured diagnostic interviews at the time of scanning to determine lifetime psychiatric diagnoses. Wechsler IQ assessments were used to assess cognitive function (Supplemental Table S3, Supplemental Methods 1).

Across sites, deletion size was determined using multiplex ligation-dependent probe amplification (MLPA)<sup>36</sup>. The large sample size here uniquely allowed for the comparison of effects of the two most frequent deletion types, the longer A-D vs. the shorter A-B deletion, on DTI measures. From cases with available MLPA data, 206 subjects had the A-D deletion (89.9%), and 15 (6.5%) subjects had the A-B deletion (see **Supplemental Table S3**).

#### 2.3. Image acquisition and processing

Acquisition parameters of dMRI and T1-weighted MRI scans for each site are shown in **Supplemental Table S4** and **S5**. All raw data were pre-processed in an identical fashion at a single site (**Supplemental Methods 2**). FA, MD, RD, and AD maps were skeletonized as described in the ENIGMA DTI protocol<sup>37,38</sup>, based on the TBSS method<sup>32</sup>, ensuring that all data are normalized to the ENIGMA-DTI template. Mean values were calculated for each DTI measure along the skeleton within each ROI defined by the Johns Hopkins University WM atlas (JHU-ICBM-DTI-81) distributed by FSL<sup>37,39</sup>. For all analyses, we used the mean of the right and left values for bilateral ROIs, for each measure; we included the mean of all WM JHU-ICBM

ROIs and we excluded the corticospinal tract, fornix and cingulum of the hippocampus as these ROIs are difficult to reliably register<sup>40</sup>. The ROIs included are shown in **Figure 1**.

### 2.4. Statistical Analyses

### 2.4.1. Effects of 22q11DS and age on DTI-derived measures

Group differences between 22q11DS and HC were investigated using two analytic approaches: a meta-analysis, which runs statistical comparisons for each site separately and combines the summary statistics across sites, and a mega-analysis, in which data are harmonized and pooled from individual subjects, and statistical analysis are run on the full group. The meta-analysis included 540 subjects: 278 22q11DS probands (mean age: 16.76 ± 6.78, 138 females) and 260 HC (mean age: 16.55 ± 8.01, 123 females) from nine independent datasets derived from eight sites (Table 1). Because Utrecht included only 22q11DS cases, it was not included in the casecontrol analyses. For each site, linear regressions were run, in which the mean DTI measure for each ROI was the dependent variable, diagnosis was the predictor of interest, and age, [agemean(age)]<sup>2</sup> and sex were included as covariates. Given that DTI-derived measures tend to peak between 11 and 20 years for commissural and association fibers and in the early twenties for projection fibers<sup>41,42</sup>, we included both the linear and guadratic effects of age in the model. The guadratic age term was centered to avoid collinearities with the linear age term. In addition, because females and males show different trajectories of DTI measures across development<sup>43</sup>, sex was accounted for in the model. Cohen's d effect sizes for diagnosis were computed. Subsequently, an inverse-variance weighted mixed-effect meta-analysis<sup>44</sup> to combine individual site effect sizes, as in<sup>40</sup>.

A pooled, or mega-analytic, approach was also conducted. As multiple factors can affect the distribution of DTI measures<sup>45-47</sup>, additional harmonization of DTI measures can be advantageous when conducting studies pooling dMRI data from different protocols. We used the COMBAT algorithm<sup>48</sup> to harmonize data across sites for each DTI measure (FA, MD, RD, AD) for each WM ROI. This algorithm uses an empirical Bayes framework to estimate additive and multiplicative site effects. It has been used previously for harmonization of multisite DTI data, and has been shown to perform better than several other methods for modeling and removing inter-site variability<sup>48</sup>. Next, group differences were assessed using the same model tested in the meta-analysis. Finally, the diagnosis-by-age interaction effect term was included in the mega-analytic model to test whether effects of age differed in 22q11DS probands relative to HC.

We used the Benjamini & Hochberg method to control for the family wise error rate<sup>49</sup>. The percentage of tolerated false positives was 5% (q<0.05). Critical p-values were calculated for each set of models, specifically: (1) meta-analysis; (2) mega-analysis; and (3) mega-analysis including diagnosis-by-age interaction. Effect sizes were derived as explained in **Supplemental Methods 3**.

Additionally, given previous findings of non-linear trajectories of DTI-derived measures with respect to age in healthy individuals (5-82 years)<sup>50</sup>, we fit a Poisson non-linear model for age for each group separately (HC and 22q11DS) for each WM ROI and for each DTI-derived measure, to further investigate age effects. We used the previously harmonized data (see above COMBAT harmonization), to reduce site effects. We measured the age of peak FA and age of minimum MD, RD and AD as in Lebel et al.<sup>50</sup> and compared both groups using a two-tailed t-test for means with outlier removal ( $\alpha$ =0.05). Thereafter, we calculated percent changes of each DTI-measure for each ROI from age 6 (minimum age in both groups) to peak/minimum, and from peak/minimum to age 46 and 52 (maximum age for 22q11DS and HC, respectively). We compared the percent changes of each DTI-measure for each and 50 each DTI-measure for all ROIs between 22q11DS and HC groups by using Yuen's method with bootstrap-t for trimmed means ( $\alpha$ =0.05).

#### 2.4.2. Influence of psychotic disorder, deletion size and IQ on DTI measures

To assess potential differences in WM architecture as a function of clinical and genetic variability, we examined the effects of psychotic illness (35 with psychotic disorder vs. 191 without psychosis) and deletion size (206 AD vs. 15 AB) on DTI measures, within individuals with 22q11DS. Additionally, given that IQ is a group-associated variable, we examined partial correlations with IQ within the 22q11DS (N=304) and HC groups (N=102) separately. For these analyses the DTI measures for each ROI were included as dependent variables. Age, [age-mean(age)]<sup>2</sup> and sex were included as covariates. FDR correction was performed as specified above (section 2.4.1).

Given the strong association between age and psychosis onset<sup>5</sup>, as well as the differences in mean age between 22q11DS cases with and without psychosis (see **Supplementary Table S2b**), to assess the effect of psychosis within the 22q11DS group we used a local nonparametric ANCOVA method<sup>51</sup> covarying for age (see **Supplemental Methods 4**). This approach allowed for a controlled test within age subgroups.

Next, in order to determine whether the microstructural changes observed in 22q11DSassociated psychosis overlap with those seen in idiopathic schizophrenia, we compared our results for 22q11DS cases with and without psychosis to schizophrenia case-control results from the ENIGMA-Schizophrenia DTI Working Group<sup>40</sup>, analyzed using the same protocols as in our study.

#### 3. Results

#### 3.1. Group differences across sites

We first investigated whether there were consistent group differences in WM microstructure between 22q11.2 deletion carriers and healthy controls, using a standardized processing pipeline. Equally important is to determine whether harmonization of the data would allow pooled analyses for further investigation of modulatory factors (psychosis, deletion size, and IQ). **Figure 2** shows group differences for 22q11DS cases vs. HC, from the meta-analysis and mega-analysis: results were nearly identical, with similar effect sizes. Effect sizes for each site are shown in **Supplementary Figure 1**. Most ROIs that significantly differed between 22q11DS and HC showed lower diffusivity values (MD, AD and RD) in 22q11DS subjects, but a mixed pattern for FA. Significantly higher FA in 22q11DS cases relative to HC was observed in the tapetum (TAP), genu (GCC), body and splenium of the corpus callosum (BCC/SCC), the anterior and posterior limb of the internal capsule (ALIC/PLIC), and posterior and superior corona radiata (PCR/SCR), with moderate to large effect sizes (d~0.3-0.8), for both analyses. In contrast, ROIs in association fibers - the superior longitudinal fasciculus (SLF), fornix/stria terminalis (FXST), and external/extreme capsules (EC) - showed significantly lower FA in 22q11DS relative to HC (**Supplementary Tables S6-S7**).

22q11DS subjects had significantly lower MD than HC in almost all ROIs investigated, with greatest effects (d~1.0) in the PCR and posterior thalamic radiation (PTR); both contain mostly thalamocortical/corticothalamic and corticofugal fibers from posterior brain areas. For all 18 ROIs, MD was lower in 22q11DS, as was AD, for 15 of the 18 ROIs. Only the PLIC showed significantly higher AD in 22q11DS relative to HC. For RD, all ROIs showing significant differences (15 of 18 ROIs) were lower in 22q11DS than HC, with largest effects (*d*~0.7) in the corpus callosum and PCR (**Supplementary Tables S6-S7**).

#### 3.2. Age-associated effects

Given the wide age range (6-52 years), we wanted to determine whether the development of WM is delayed or altered in 22q11DS. As shown in **Supplementary Table S6**, there were highly significant linear effects of age for all indices for the majority of ROIs. FA increased with age, while the opposite pattern was found for diffusivity values (MD, AD and RD). There were

also significant quadratic effects for almost all ROIs for FA, MD and RD. AD showed fewer significant quadratic effects, in both the meta- and mega-analysis. However, no significant ageby-diagnosis interactions were observed (**Supplementary Table S8**). Given the sparse representation of older adults, we also performed a mega-analysis with a subsample of subjects under 30 years old to explore potential age-by-diagnosis effects, which yielded similar results (**Supplementary Table S9**).

We also investigated Poisson regression models to further evaluate effects of age on WM development. These models did not provide a substantially better fit to the data than the linear regression model used above, as determined by the residual standard error of the fits (see **Supplementary Tables S10, S11, S12**). As such, we retained the linear regression models for our primary analyses, but report the additional trajectory information obtained from the Poisson models below.

Scatterplots for the non-linear Poisson fits of age per ROI for each DTI-derived measure are displayed in **Supplementary Figures S2-S5**. There were fewer ROIs with significant peak/minimum estimates in the 22q11DS group, across all DTI indices (see **Supplementary Tables S13, S14**). Generally, those ROIs without significant peak/minimum estimates have linear rather than exponential growth and decay trajectories. When comparing the mean age of peak FA (across ROIs) between HC and 22q11DS, average peak FA was significantly delayed in 22q11DS. We found significantly delayed mean age at minimum RD in 22q11DS, but no differences in minimum MD and AD. Mean rate of FA decrease (after peak FA), and mean rate of increase in RD and MD (after minimum RD/MD), were also significantly greater in HC vs. 22q11DS, with no differences in AD (**Supplementary Table S15**).

#### 3.3. Influence of psychosis

Are the deletion-related WM changes more severe in those with psychotic disorder? Relative to 22q11DS subjects without psychosis, 22q11DS subjects with psychotic disorder showed overall lower diffusivity values, with significantly lower AD in the ALIC and PTR, both predominantly containing thalamic radiation fibers, in the cingulum of the cingulate gyrus (CGC) and the SLF, which mostly contain fronto-parietal and fronto-temporal association fibers, and the sagittal stratum (SS), which contains both posterior thalamic projection and temporal association fibers. 22q11DS-Psychosis was also associated with significantly lower RD and MD in the GCC, which contains callosal fibers, and significantly lower MD in the PLIC, where the superior thalamic radiation and cortico-pontine fibers are the major constituents. These differences were seen primarily between ages 20 and 26 for most ROIs; some ROIs (ALIC, PTR

and SS) showed differences by age 16-17 (**Figure 3** and **Supplementary Table S16**). Overall, these findings confirm that WM changes detected by DTI diffusivity measures are more severe in 22q11DS patients with psychotic disorder, and are particularly evident in young adulthood.

#### 3.4. Comparison of WM Microstructure in 22q11DS-Psychosis to Idiopathic Schizophrenia

Next, we compared our results for 22q11DS cases with and without psychosis to schizophrenia case-control results (2359 HC vs. 1963 schizophrenia patients)<sup>40</sup>, plotted together for visualization purposes (**Figure 4**). Effects for 22q11DS cases with and without psychosis differed markedly from those observed for idiopathic schizophrenia relative to HC. Specifically, while patients with 22q11DS-psychosis tended toward higher FA and lower diffusivity values compared to 22q11DS individuals without psychosis, patients with idiopathic schizophrenia showed overall lower FA across tracts and increased diffusivity values relative to HC, particularly for MD and RD.

#### 3.3. Influence of deletion type and IQ

Does the extent of the deletion affect WM microstructure? Subjects with the large A-D deletion showed a trend toward lower AD in the anterior corona radiata (ACR) and EC, and higher FA in the TAP; however, there were no statistically significant differences as a function of deletion size, after multiple comparison correction (see **Supplementary Figure S6** and **Supplementary Table S17)**.

Additionally, regarding relationships between DTI indices and cognitive abilities, healthy controls showed trends toward positive correlations of MD, RD and AD in multiple ROIs with IQ, and a trend toward an inverse correlation of FA with IQ in the TAP. Within 22q11DS cases, findings were similar, but higher IQ was associated with significantly higher AD in the PTR, which contains mainly posterior cortico-thalamic and thalamo-cortical fibers. There was also a trend toward higher AD in average WM, genu of the CC, and SS being associated with higher IQ in 22q11DS (**Supplementary Figure S7**, **Supplementary Table S18**). While these relationships were not significant when corrected for multiple comparisons, the overall pattern of findings suggests that relationships between WM microstructure and cognition may differ in 22q11DS relative to typically developing controls.

#### 4. Discussion

This is the largest study to date of WM microstructure in 22q11DS (334 22q11DS cases and 260 HC), assessed by DTI. Our analysis pipeline<sup>37,40</sup> allowed for coordinated prospective

meta- and mega-analyses of the data across sites, unlike traditional meta-analyses that combine statistical results from the literature. This approach addresses, for the first time, issues of low power due to small sample sizes and variable analysis protocols that contribute to heterogeneity and lack of clarity in DTI studies to date.

In contrast to findings in many neuropsychiatric disorders<sup>40,52</sup>, our findings revealed overall lower DTI diffusivities (AD, RD and MD) in 22q11DS compared to HC, with regionally varying directions of effect for FA. Higher FA, lower RD and AD (and consequently, lower MD) appear to be the hallmark of microstructural alterations in the major WM tracts in 22g11DS, especially in the commissural fibers of the corpus callosum. While this may suggest greater myelination<sup>13</sup>, we must be cautious in applying this interpretation to our findings, given that dMRI cannot directly index the degree of myelination<sup>53</sup>. Anisotropy does not only depend on the presence of myelin in the WM, as it has been demonstrated in unmyelinated tracts<sup>54</sup> and is also sensitive to axonal density. RD is sensitive to axonal density and amount of extracellular space, and AD to axonal diameter and organization<sup>12,55</sup>. Moreover, since axonal density and myelination are correlated<sup>54,56</sup>, it is not possible to disentangle one from another when interpreting FA and RD differences between populations. We postulate that the observed group differences may result from an increase in the cumulative cellular membrane circumference<sup>57</sup> in 22q11DS (attributable to differences in axon composition, myelination and/or reactive astrocytes), which hinders diffusion perpendicularly to the WM tracts, hence increasing anisotropy and decreasing RD.

Our findings of higher FA in 22q11DS relative to controls in ROIs in commissural tracts (TAP, GCC, BCC, SCC), no detectable differences in ROIS where projection fibers predominate (RLIC, SS, PTR, SFO), and lower FA in ROIs in long association tracts (EC, SLF, FXST) are consistent with findings in the mouse model of 22q11DS<sup>9</sup>. Specifically, this study found that proliferation of basal, but not apical progenitors is disrupted, and subsequently the frequency of projection neurons in layers 2/3, but not layers 5/6, is altered. Commissural and long association fibers originate primarily from projection neurons, i.e., pyramidal neurons in the outer layers 2/3, whereas corticofugal and cortico-thalamic projection fibers tend to originate from pyramidal cells in cortical layers 5/6. Moreover, our results suggest that the nature of WM disruptions may differ between callosal and long association fibers in 22q11DS, but advanced microstructural MRI techniques may be necessary to disentangle these differences. As such, these cross-species findings collectively suggest a potential neurobiological model in which haploinsufficiency at the 22q11.2 locus leads to disruptions of specific aspects of early brain

development, and subsequent changes in neural circuitry that likely elevate risk for neuropsychiatric disorders in 22q11DS patients.

We speculate that our findings may be related to three types of histopathological alterations in WM of 22q11DS patients, all of which could reduce diffusivity. First, a recent neuropathology study of a 3-month old infant with 22g11DS reported decreased neuronal frequencies in outer cortical layers and increased neuronal frequencies in deeper cortical layers<sup>9</sup>. This is closely related to findings in the LgDel 22q11.2 mouse model mentioned above<sup>9</sup>. Pyramidal neurons of cortical layers 2/3 generate a substantial portion of the cortico-cortical axonal projections between association areas<sup>58</sup>. These axons are present in most of the WM ROIs included in this study. Consequently, target-to-origin signaling between cortical association areas (cortico-cortical projections) may be disrupted in 22q11DS, affecting the necessary cues to initiate proper axonal differentiation<sup>59,60</sup>, ultimately affecting the development of a typical distribution of axonal diameters<sup>61-63</sup>, and therefore altering RD and AD in WM bundles. Moreover, the PLIC was the only ROI showing higher AD in 22q11DS. AD has been associated with axonal diameter changes and axonal tortuosity in rats<sup>12,55</sup>. PLIC is the only ROI in this study that contains mostly corticofugal fibers, which primarily derive from cortical layers  $5/6^{39,58}$ , suggesting that the axonal size distribution within fiber bundles originating in the deeper cortical layers may differ from those originating in the outer cortical layers<sup>61,63</sup>. Further studies of animal models and post-mortem human brain tissue may shed light on this.

Second, DTI abnormalities may also reflect gliotic changes secondary to microvascular insults. Post-mortem findings in 22q11DS adults indicate both deep WM gliosis associated with cerebrovascular changes<sup>64</sup>. Gliosis - occurring as brain reacts to microvascular injuries - has been associated with increased anisotropy in a mouse brain injury model<sup>65</sup>. Third, DTI measures may be affected by ectopic neurons in WM that may result from neuronal migration defects during early development<sup>66</sup>. These have been reported in both neuropathologic<sup>64,67,68</sup> and neuroimaging studies of 22q11DS patients<sup>69,70</sup>. While we did not detect any heterotopias in our cohort, subtle microscopic ones may be detected only via histology.

The age trajectories of FA MD, RD and AD, as well as peak and minimum age estimates of our control sample, were similar to those reported previously<sup>50</sup>. However, 22q11DS patients showed a delayed mean age of both peak FA and minimum RD; correspondingly, they also showed lower decrease and increase rates for FA and MD after peak and minimum ages, respectively. As noted above, these findings may indicate a delay in maturation secondary to altered axonal diameters and organization in the deep WM, which could be precursors of a delayed myelination process. Conversely, lower rate of change after maturation (indicated by

peak FA and minimum RD) may be indicative of underlying organizational changes in WM that abnormally hinder diffusion and may result from gliotic changes, as has been reported in adult post-mortem 22q11DS brain tissue<sup>64</sup>. Nevertheless, despite the harmonization protocol interpretive caution is warranted because the age distribution was variable across sites and data points were rather sparse in the higher age ranges.

Consistent with some single-site studies suggesting inverse correlations between psychotic symptom severity in 22q11DS and diffusivity in the CC and long association tracts<sup>25,29–31,33</sup>, we found lower RD and MD in those with psychosis in the genu of the CC, and lower axial diffusivity in long association tracts such as the SLF and CGC. Interestingly, significantly lower AD was found in ROIs with predominantly cortico-thalamic and thalamo-cortical fibers such as the ALIC, SS and the PTR. A previous single-site tractometry study found significant associations between higher FA and lower RD in the ALIC with positive prodromal symptoms<sup>29</sup>. Future studies should prospectively investigate the role of the major thalamic projection tracts in the emergence and progression of psychotic symptoms in 22q11DS.

Notably, WM microstructural alterations in 22q11DS with psychosis showed a largely opposite pattern from those seen in idiopathic schizophrenia, involving primarily FA increases rather than decreases and reductions (rather than increases) in diffusivity measures. A previous single site study of 22q11DS and youth at clinical high risk for psychosis reported this directionally opposite pattern as well<sup>24</sup>. This is in contrast to findings for cortical gray matter, in which 22q11DS patients with psychosis showed highly significant overlap with idiopathic schizophrenia, in terms of prominent cortical thinning in fronto-temporal regions<sup>35</sup>. Thus, our findings suggest that patterns of neuroanatomic overlap in 22q11DS-associated vs. idiopathic psychosis markedly differ for gray and WM, and suggest that different WM phenotypes may lead to similar downstream clinical outcomes. Our findings of altered AD in 22q11DS, more extreme in those with psychosis, may indicate altered axonal diameter and increased tortuosity of WM tracts<sup>12,55</sup>. Numerous smaller, tortuous axons in key connections between cortical association areas may lead to altered WM maturation, structural dysconnectivity and possibly psychosis. In idiopathic schizophrenia, WM degeneration (demyelination and loss of axons with larger diameters) may also lead to disrupted axonal morphology that similarly results in structural dysconnectivity between cortical association areas.

We did not see consistent effects of deletion size on WM architecture, and found little evidence that the relationship between WM microstructure and IQ differed between 22q11DS cases and HC. Sample size was quite limited for the A-B deletion type, and imaging protocols varied across sites, which may have affected our results. Additionally, given highly variable

psychotropic medications and medical comorbidities in 22q11DS patients, their effects could not be systematically investigated here. Previously, in a sample including many of the same participants as in the current analysis, we found that psychotropic medication was not significantly associated with cortical thickness or cortical surface area in 22q11DS patients<sup>35</sup>. Additionally, prior studies of patients with idiopathic schizophrenia found that WM changes detected by DTI were not attributable to antipsychotic medication<sup>40,71</sup>.

Future studies with multi-shell acquisitions and novel biophysical models may resolve the contribution of the intra- and extra-axonal volume fractions and axonal diameters to these abnormalities<sup>72,73</sup>. Quantitative magnetization transfer<sup>74</sup> and perfusion MRI acquisitions<sup>75</sup> may help clarify any myelin abnormalities or underlying brain microvascular pathology in 22q11DS.

Collectively, our findings indicate large effects of the 22q11.2 deletion on WM microstructure. Diffusivity was more consistently affected than FA. In animal models, disruptions to predominantly cortico-cortical and cortico-thalamic/thalamo-cortical connections in 22q11DS may be attributable to disrupted early neurogenesis. Future translational studies will help to determine the neurobiological underpinnings of these alterations.

#### Acknowledgments and Funding Sources

The 22q- ENIGMA working group gratefully acknowledges support from the NIH Big Data to Knowledge (BD2K) award (U54 EB020403 to PMT). This manuscript was also supported by grants from the National Institute of Mental Health: RO1 MH085953 and R01MH100900 (CEB), the Miller Family Endowed Term Chair at the UCLA Brain Research Institute (CEB), Neurobehavioral Genetics Predoctoral Training Grant (5T32MH073526) to CC and AL, NIMH grant 5U01MH101723-02; NIH U01 MH087626 (REG), U01MH101719 (REG), MH089983 (REG); U01 MH087636 (BE and DMcD), the Wellcome Trust Institutional Strategic Support Fund (ISSF to MvdB), the Waterloo Foundation (WF 918-1234 to MvdB), the Baily Thomas Charitable Fund (2315/1 to MvdB), Wellcome Trust (102003/Z/13/Z to JD), National Institute of Mental Health (NIMH 5U01MH101724 to MvdB and MO), Wellcome Trust (100202/Z/12/Z to MO). We thank the participants and their families for being a part of our research. We also thank the ENIGMA-Schizophrenia Working Group for sharing their data for comparative analysis.

#### Conflicts of Interest

Ms. McDonald-McGinn is a member of the Speaker's Bureau for Natera. Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Ambrosseti, Gedeon Richter, Janssen Cilag, Lundbeck, Merck, Otsuka, Roche, Servier, Shire, Schering Plough, Sumitomo

Dainippon Pharma, Sunovion and Takeda. The remaining authors declare that they have no conflict of interest.

Supplementary information is available at Molecular Psychiatry's website.

Supplements:

- Supplement 1: Supplementary Methods
- Supplement 2: Supplementary Figure and Table Legends
- Supplement 3: Supplementary Tables S1-S18
- Supplement 4: Supplementary Figures S1-S7

Author contributions: Protocol design: JVR, PMT, CEB Data processing and statistical analysis: JVR, KM, NJ, XQ Data collection and funding: All authors Manuscript preparation: JVR, NJ, JF, CC, LK, PMT, CEB Critical revisions of manuscript content: All authors All authors contributed edits and approved the content of the manuscript.

#### References

- 1 McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JAS *et al.* 22q11.2 deletion syndrome. *Nat Rev Dis Primers* 2015; **1**: 15071.
- 2 Oskarsdóttir S, Vujic M, Fasth A. Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden. Arch Dis Child 2004; 89: 148– 151.
- 3 Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA *et al.* A Population-Based Study of the 22q11.2 Deletion: Phenotype, Incidence, and Contribution to Major Birth Defects in the Population. *Pediatrics* 2003; **112**: 101–107.
- 4 Murphy KC, Owen MJ. Velo-cardio-facial syndrome: a model for understanding the genetics and pathogenesis of schizophrenia. *Br J Psychiatry* 2001; **179**: 397–402.
- 5 Schneider M, Debbané M, Bassett AS, Chow EWC, Fung WLA, van den Bree M *et al.* Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. *Am J Psychiatry* 2014; **171**: 627–639.
- 6 Bassett AS, Chow EWC, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R. The schizophrenia phenotype in 22q11 deletion syndrome. *Am J Psychiatry* 2003; **160**: 1580– 1586.
- 7 Chow EW, Bassett AS, Weksberg R. Velo-cardio-facial syndrome and psychotic disorders: implications for psychiatric genetics. *Am J Med Genet* 1994; **54**: 107–112.
- Morgan VA, Leonard H, Bourke J, Jablensky A. Intellectual disability co-occurring with schizophrenia and other psychiatric illness: population-based study. *Br J Psychiatry* 2008; 193: 364–372.
- 9 Meechan DW, Tucker ES, Maynard TM, LaMantia A-S. Diminished dosage of 22q11 genes disrupts neurogenesis and cortical development in a mouse model of 22q11 deletion/DiGeorge syndrome. *Proc Natl Acad Sci U S A* 2009; **106**: 16434–16445.
- 10 Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. *Neurotherapeutics* 2007; **4**: 316–329.
- 11 Kinoshita Y, Ohnishi A, Kohshi K, Yokota A. Apparent diffusion coefficient on rat brain and nerves intoxicated with methylmercury. *Environ Res* 1999; **80**: 348–354.
- 12 Schwartz ED, Cooper ET, Fan Y, Jawad AF, Chin C-L, Nissanov J *et al.* MRI diffusion coefficients in spinal cord correlate with axon morphometry. *Neuroreport* 2005; **16**: 73–76.
- 13 Song S-K, Sun S-W, Ju W-K, Lin S-J, Cross AH, Neufeld AH. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. *Neuroimage* 2003; **20**: 1714–1722.
- 14 Harsan LA, Poulet P, Guignard B, Parizel N, Skoff RP, Ghandour MS. Astrocytic

hypertrophy in dysmyelination influences the diffusion anisotropy of white matter. *J Neurosci Res* 2007; **85**: 935–944.

- 15 Nair G, Tanahashi Y, Low HP, Billings-Gagliardi S, Schwartz WJ, Duong TQ. Myelination and long diffusion times alter diffusion-tensor-imaging contrast in myelin-deficient shiverer mice. *Neuroimage* 2005; **28**: 165–174.
- 16 Latour LL, Svoboda K, Mitra PP, Sotak CH. Time-dependent diffusion of water in a biological model system. *Proc Natl Acad Sci U S A* 1994; **91**: 1229–1233.
- 17 da Silva Alves F, Schmitz N, Bloemen O, van der Meer J, Meijer J, Boot E *et al.* White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia. *Schizophr Res* 2011; **132**: 75–83.
- 18 Kikinis Z, Asami T, Bouix S, Finn CT, Ballinger T, Tworog-Dube E *et al.* Reduced fractional anisotropy and axial diffusivity in white matter in 22q11.2 deletion syndrome: a pilot study. *Schizophr Res* 2012; **141**: 35–39.
- 19 Radoeva PD, Coman IL, Antshel KM, Fremont W, McCarthy CS, Kotkar A *et al.* Atlasbased white matter analysis in individuals with velo-cardio-facial syndrome (22q11.2 deletion syndrome) and unaffected siblings. *Behav Brain Funct* 2012; **8**: 38.
- 20 Villalon-Reina J, Jahanshad N, Beaton E, Toga AW, Thompson PM, Simon TJ. White matter microstructural abnormalities in girls with chromosome 22q11.2 deletion syndrome, Fragile X or Turner syndrome as evidenced by diffusion tensor imaging. *Neuroimage* 2013; 81: 441–454.
- 21 Deng Y, Goodrich-Hunsaker NJ, Cabaral M, Amaral DG, Buonocore MH, Harvey D *et al.* Disrupted fornix integrity in children with chromosome 22q11.2 deletion syndrome. *Psychiatry Res* 2015; **232**: 106–114.
- 22 Roalf DR, Eric Schmitt J, Vandekar SN, Satterthwaite TD, Shinohara RT, Ruparel K *et al.* White matter microstructural deficits in 22q11.2 deletion syndrome. *Psychiatry Res Neuroimaging* 2017; **268**: 35–44.
- 23 Simon TJ, Wu Z, Avants B, Zhang H, Gee JC, Stebbins GT. Atypical cortical connectivity and visuospatial cognitive impairments are related in children with chromosome 22q11.2 deletion syndrome. *Behav Brain Funct* 2008; **4**: 25.
- 24 Bakker G, Caan MWA, Schluter RS, Bloemen OJN, da Silva-Alves F, de Koning MB *et al.* Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosis. *Psychol Med* 2016; **46**: 2299–2311.
- 25 Olszewski AK, Kikinis Z, Gonzalez CS, Coman IL, Makris N, Gong X *et al.* The social brain network in 22q11.2 deletion syndrome: a diffusion tensor imaging study. *Behav Brain Funct* 2017; **13**: 4.
- 26 Barnea-Goraly N, Menon V, Krasnow B, Ko A, Reiss A, Eliez S. Investigation of white matter structure in velocardiofacial syndrome: a diffusion tensor imaging study. *Am J Psychiatry* 2003; **160**: 1863–1869.
- 27 Simon TJ, Ding L, Bish JP, McDonald-McGinn DM, Zackai EH, Gee J. Volumetric,

connective, and morphologic changes in the brains of children with chromosome 22q11.2 deletion syndrome: an integrative study. *Neuroimage* 2005; **25**: 169–180.

- 28 Sundram F, Murphy DG, Murphy KC. White matter microstructure in children with Velocardiofacial Syndrome: A Diffusion Tensor Imaging and Voxel Based Morphometry study. J Intellect Disabil Res 2008; 52: 812–812.
- 29 Perlstein MD, Chohan MR, Coman IL, Antshel KM, Fremont WP, Gnirke MH *et al.* White matter abnormalities in 22q11.2 deletion syndrome: preliminary associations with the Nogo-66 receptor gene and symptoms of psychosis. *Schizophr Res* 2014; **152**: 117–123.
- 30 Jalbrzikowski M, Villalon-Reina JE, Karlsgodt KH, Senturk D, Chow C, Thompson PM *et al.* Altered white matter microstructure is associated with social cognition and psychotic symptoms in 22q11.2 microdeletion syndrome. *Front Behav Neurosci* 2014; **8**: 393.
- 31 Kates WR, Olszewski AK, Gnirke MH, Kikinis Z, Nelson J, Antshel KM *et al.* White matter microstructural abnormalities of the cingulum bundle in youths with 22q11.2 deletion syndrome: associations with medication, neuropsychological function, and prodromal symptoms of psychosis. *Schizophr Res* 2015; **161**: 76–84.
- 32 Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE *et al.* Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. *Neuroimage* 2006; **31**: 1487–1505.
- 33 Kikinis Z, Cho KIK, Coman IL, Radoeva PD, Bouix S, Tang Y *et al.* Abnormalities in brain white matter in adolescents with 22q11.2 deletion syndrome and psychotic symptoms. *Brain Imaging Behav* 2017; **11**: 1353–1364.
- 34 Tylee DS, Kikinis Z, Quinn TP, Antshel KM, Fremont W, Tahir MA *et al.* Machine-learning classification of 22q11.2 deletion syndrome: A diffusion tensor imaging study. *Neuroimage Clin* 2017; **15**: 832–842.
- 35 Sun D, Ching CRK, Lin A, Forsyth JK, Kushan L, Vajdi A *et al.* Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size. *Mol Psychiatry* 2018. doi:10.1038/s41380-018-0078-5.
- 36 Sørensen KM, Agergaard P, Olesen C, Andersen PS, Larsen LA, Ostergaard JR et al. Detecting 22q11.2 deletions by use of multiplex ligation-dependent probe amplification on DNA from neonatal dried blood spot samples. J Mol Diagn 2010; 12: 147–151.
- 37 Jahanshad N, Kochunov PV, Sprooten E, Mandl RC, Nichols TE, Almasy L *et al.* Multi-site genetic analysis of diffusion images and voxelwise heritability analysis: a pilot project of the ENIGMA-DTI working group. *Neuroimage* 2013; **81**: 455–469.
- 38 DTI Protocols « ENIGMA. http://enigma.ini.usc.edu/protocols/dti-protocols/ (accessed 31 Jul2018).
- 39 Mori S, Oishi K, Jiang H, Jiang L, Li X, Akhter K *et al.* Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. *Neuroimage* 2008; **40**: 570–582.
- 40 Kelly S, Jahanshad N, Zalesky A, Kochunov P, Agartz I, Alloza C *et al.* Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the

ENIGMA Schizophrenia DTI Working Group. Mol Psychiatry 2018; 23: 1261–1269.

- 41 Lebel C, Walker L, Leemans A, Phillips L, Beaulieu C. Microstructural maturation of the human brain from childhood to adulthood. *Neuroimage* 2008; **40**: 1044–1055.
- 42 Kochunov P, Glahn DC, Lancaster JL, Winkler AM, Smith S, Thompson PM *et al.* Genetics of microstructure of cerebral white matter using diffusion tensor imaging. *Neuroimage* 2010; 53: 1109–1116.
- 43 Simmonds DJ, Hallquist MN, Asato M, Luna B. Developmental stages and sex differences of white matter and behavioral development through adolescence: a longitudinal diffusion tensor imaging (DTI) study. *Neuroimage* 2014; **92**: 356–368.
- 44 Homepage [The metafor Package]. http://www.metafor-project.org/doku.php (accessed 31 Jul2018).
- 45 Zhu T, Hu R, Qiu X, Taylor M, Tso Y, Yiannoutsos C *et al.* Quantification of accuracy and precision of multi-center DTI measurements: a diffusion phantom and human brain study. *Neuroimage* 2011; **56**: 1398–1411.
- 46 Zhan L, Leow AD, Jahanshad N, Chiang M-C, Barysheva M, Lee AD *et al.* How does angular resolution affect diffusion imaging measures? *Neuroimage* 2010; **49**: 1357–1371.
- 47 Jahanshad N, Zhan L, Bernstein MA, Borowski BJ, Jack CR, Toga AW *et al.* Diffusion tensor imaging in seven minutes: Determining trade-offs between spatial and directional resolution. In: *2010 IEEE International Symposium on Biomedical Imaging: From Nano to Macro.* 2010, pp 1161–1164.
- 48 Fortin J-P, Parker D, Tunç B, Watanabe T, Elliott MA, Ruparel K *et al.* Harmonization of multi-site diffusion tensor imaging data. *Neuroimage* 2017; **161**: 149–170.
- 49 Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Series B Stat Methodol* 1995; **57**: 289–300.
- 50 Lebel C, Gee M, Camicioli R, Wieler M, Martin W, Beaulieu C. Diffusion tensor imaging of white matter tract evolution over the lifespan. *Neuroimage* 2012; **60**: 340–352.
- 51 Wilcox R. Chapter 11 More Regression Methods. In: Wilcox R (ed). *Introduction to Robust Estimation and Hypothesis Testing (Fourth Edition)*. Academic Press, 2017, pp 585–691.
- 52 Vederine F-E, Wessa M, Leboyer M, Houenou J. A meta-analysis of whole-brain diffusion tensor imaging studies in bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2011; **35**: 1820–1826.
- 53 Laule C, Vavasour IM, Kolind SH, Li DKB, Traboulsee TL, Moore GRW *et al.* Magnetic resonance imaging of myelin. *Neurotherapeutics* 2007; **4**: 460–484.
- 54 Beaulieu C. The basis of anisotropic water diffusion in the nervous system--a technical review. *NMR Biomed* 2002; **15**: 435–455.
- 55 Takahashi M, Ono J, Harada K, Maeda M, Hackney DB. Diffusional anisotropy in cranial nerves with maturation: quantitative evaluation with diffusion MR imaging in rats. *Radiology* 2000; **216**: 881–885.

- 56 Mottershead JP, Schmierer K, Clemence M, Thornton JS, Scaravilli F, Barker GJ *et al.* High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cord. *J Neurol* 2003; **250**: 1293–1301.
- 57 Concha L, Livy DJ, Beaulieu C, Wheatley BM, Gross DW. In vivo diffusion tensor imaging and histopathology of the fimbria-fornix in temporal lobe epilepsy. *J Neurosci* 2010; **30**: 996–1002.
- 58 Pandya DN, Yeterian EH. Architecture and Connections of Cortical Association Areas. In: Peters A, Jones EG (eds). Association and Auditory Cortices. Springer US: Boston, MA, 1985, pp 3–61.
- 59 Innocenti GM, Vercelli A, Caminiti R. The diameter of cortical axons depends both on the area of origin and target. *Cereb Cortex* 2014; **24**: 2178–2188.
- 60 Berbel P, Innocenti GM. The development of the corpus callosum in cats: a light- and electron-microscopic study. *J Comp Neurol* 1988; **276**: 132–156.
- 61 LaMantia A-S, Rakic P. Cytological and quantitative characteristics of four cerebral commissures in the rhesus monkey. *J Comp Neurol* 1990; **291**: 520–537.
- 62 LaMantia AS, Rakic P. Axon overproduction and elimination in the corpus callosum of the developing rhesus monkey. *J Neurosci* 1990; **10**: 2156–2175.
- 63 Aboitiz F, Scheibel AB, Fisher RS, Zaidel E. Fiber composition of the human corpus callosum. *Brain Res* 1992; **598**: 143–153.
- 64 Kiehl TR, Chow EWC, Mikulis DJ, George SR, Bassett AS. Neuropathologic features in adults with 22q11.2 deletion syndrome. *Cereb Cortex* 2009; **19**: 153–164.
- 65 Budde MD, Janes L, Gold E, Turtzo LC, Frank JA. The contribution of gliosis to diffusion tensor anisotropy and tractography following traumatic brain injury: validation in the rat using Fourier analysis of stained tissue sections. *Brain* 2011; **134**: 2248–2260.
- 66 Meechan DW, Tucker ES, Maynard TM, LaMantia A-S. Cxcr4 regulation of interneuron migration is disrupted in 22q11.2 deletion syndrome. *Proc Natl Acad Sci U S A* 2012; **109**: 18601–18606.
- 67 Wu P, Teot L, Murdoch G, Monaghan-Nichols AP, McFadden K. Neuropathology of 22q11 deletion syndrome in an infant. *Pediatr Dev Pathol* 2014; **17**: 386–392.
- 68 Baharnoori M, Mandell DM, Andrade DM, Chow EWC, Bassett AS, Kiehl T-R. Periventricular nodular heterotopia and bilateral intraventricular xanthogranulomas in 22q11.2 deletion syndrome. *Human Pathology: Case Reports* 2017; **9**: 55–57.
- 69 van Kogelenberg M, Ghedia S, McGillivray G, Bruno D, Leventer R, Macdermot K et al. Periventricular heterotopia in common microdeletion syndromes. *Mol Syndromol* 2010; 1: 35–41.
- 70 Andrade DM, Krings T, Chow EWC, Kiehl T-R, Bassett AS. Hippocampal malrotation is associated with chromosome 22q11.2 microdeletion. *Can J Neurol Sci* 2013; **40**: 652–656.
- 71 Karlsgodt KH, van Erp TGM, Poldrack RA, Bearden CE, Nuechterlein KH, Cannon TD.

Diffusion tensor imaging of the superior longitudinal fasciculus and working memory in recent-onset schizophrenia. *Biol Psychiatry* 2008; **63**: 512–518.

- 72 Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. *Neuroimage* 2012; 61: 1000–1016.
- 73 Kaden E, Kruggel F, Alexander DC. Quantitative mapping of the per-axon diffusion coefficients in brain white matter. *Magn Reson Med* 2016; **75**: 1752–1763.
- 74 Geeraert BL, Lebel RM, Mah AC, Deoni SC, Alsop DC, Varma G *et al.* A comparison of inhomogeneous magnetization transfer, myelin volume fraction, and diffusion tensor imaging measures in healthy children. *Neuroimage* 2017. doi:10.1016/j.neuroimage.2017.09.019.
- 75 Telischak NA, Detre JA, Zaharchuk G. Arterial spin labeling MRI: clinical applications in the brain. *J Magn Reson Imaging* 2015; **41**: 1165–1180.

### Table 1 caption

**Table 1. Demographic information of study participants.** Demographic information of study participants, per site. SD = standard deviation; M = Male; F = Female, HC = Healthy Controls. (1) University of Pennsylvania/Children's Hospital of Philadelphia (PA, USA); (2) University California Los Angeles (CA, USA); (3) State University New York Upstate (NY, USA); (4) University of Newcastle (NSW, Australia); (5) Maastricht University (Netherlands); (6) Institute of Psychiatry (London, UK); (7) University California Davis #1 (CA, USA); (8) University California Davis #2 (CA, USA); (9) Cardiff Univ. (WAL, UK); (10) Utrecht Univ. (The Netherlands).

#### Figure captions (in order of appearance below)

**Figure 1.** Depiction of the 18 regions of interest (ROIs) of the Johns Hopkins University (JHU-ICBM) white matter atlas [Mori et al. (2008)] that were analyzed in the present study.

**Figure 2.** Results of meta- and mega-analysis including nine independent datasets from the ENIGMA-22q11DS working group. The bar graphs on the left side are organized based on the effect sizes for FA (positive to negative, from left to right). The brain maps on the right side are organized by rows, each one corresponding to respective bar graph on the left. These show the JHU-ICBM atlas white matter ROIs that passed multiple comparison correction after meta-analysis. The model tested was:

DTI-ROI-measure= $\beta_0 + \beta_1Diagnosis+\beta_2Sex+\beta_3Age+\beta_4Age_{centered}$ **WM** = Average of all white matter JHU-ICBM ROIs.

**Figure 3.** Results from the local nonparametric ANCOVA analysis comparing 22q11DS subjects with psychotic disorder (N=35) vs. those with no lifetime history of psychotic symptoms (N=191). Shown here are the results for DTI indices that significantly differed between 22q-Psychosis vs. 22q-No Psychosis: AD in the ALIC, CGC, PTR, SLF and SS, RD in GCC, and MD in the GCC and PLIC. All analyses were performed on 25 design points corresponding to different age bands. Vertical red lines correspond to the ages at which these DTI measures (AD, MD, RD) significantly differed between subjects with 22q11DS with and without psychosis.

**Figure 4.** Comparison of Effect Sizes in this study, to those from the ENIGMA-Schizophrenia DTI Working Group using similar methods (2,359 healthy controls vs. 1,963 schizophrenia patients from 29 independent studies; Kelly et al. 2018; blue triangles) to 22q11DS probands with and without psychosis (red circles). Positive effect sizes: 22q-Psychosis > 22q-No Psychosis OR Schizophrenia Patients > Healthy Controls. Negative effect sizes: 22q-Psychosis > 22q-No Psychosis > 22q-Psychosis OR Healthy Controls > Schizophrenia Patients.

**Table 1. Demographic information of study participants.** Demographic information of study participants, per site. SD = standard deviation; M = Male; F = Female, HC = Healthy Controls. (1) University of Pennsylvania/Children's Hospital of Philadelphia (PA, USA); (2) University California Los Angeles (CA, USA); (3) State University New York Upstate (NY, USA); (4) University of Newcastle (NSW, Australia); (5) Maastricht University (Netherlands); (6) Institute of Psychiatry (London, UK); (7) University California Davis #1 (CA, USA); (8) University California Davis #2 (CA, USA); (9) Cardiff Univ. (WAL, UK); (10) Utrecht Univ. (The Netherlands).

Healthy Controls (HC)					22q11.2 DS				
Site	N	N (% by Sex)	Mean Age (SD)	Mean IQ (SD)	N	N (% by Sex)	Mean Age (SD)	Mean IQ (SD)	Group Differences
UPenn	49	30 (61.2%) M; 19 (38.8%) F	17.31 (3.22)	_	43	26 (60%) M; 17 (40%) F	17.49 (3.13)	77.16 (10.96)	Age: <i>t</i> = 0.27 ( <i>p</i> = 0.79) Sex: <i>X</i> <sup>2</sup> = 0.01( <i>p</i> = 0.94) IQ: NA
UCLA	32	16 (50%) M; 16 (50%) F	12.59 (5.62)	111.97 (21.69)	49	25 (51%) M; 24 (49%) F	14.69 (5.59)	76.55 (12.61)	Age: $t = 1.60 \ (p = 0.11)$ Sex: $X^2 = 0.02(p = 0.89)$ IQ: $t = -9.11 \ (p < 0.0005)$
SUNY Upstate	11	5 (45.45%) M; 6 (54.5%) F	21.12 (2.01)	87.77 (16.25)	34	19 (55.8%) M; 15 (44.11%) F	20.85 (1.86)	78.31 (13.72)	Age: $t = -0.43$ ( $p = 0.67$ ) Sex: $X^2 = 0.49$ ( $p = 0.48$ ) IQ: $t = -1.99$ ( $p = 0.06$ )
University of Newcastle	17	8 (47.1%) M; 9 (52.9%) F	17.06 (3.01)	106.63 (17.58)	16	6 (37.5%) M; 10 (62.5%) F	16.63 (2.75)	72.63 (13.45)	Age: $t = -0.43$ ( $p = 0.67$ ) Sex: $X^2 = 0.31$ ( $p = 0.58$ ) IQ: $t = -6.14$ ( $p < .0005$ )
Maastricht University	36	23 (63.8%) M; 13 (36.2%) F	29.97 (10.05)	105.13 (14.13)	24	11 (45.9%) M; 13 (54.1%) F	30.05 (7.86)	74.42 (9.76)	Age: <i>t</i> = 0.04 ( <i>p</i> = 0.97) Sex: <i>X</i> <sup>2</sup> = 1.91( <i>p</i> = 0.17) IQ: <i>t</i> = -8.14 ( <i>p</i> <.0005)
Institute of Psychiatry London	24	10 (41.7) % M; 14 (58.3%) F	18.36 (6.73)	115.92 (15.03)	24	13 (54.1%) M; 11 (45.9%) F	18.04 (6.88)	84.46 (14.15)	Age: $t = -0.16(p = 0.87)$ Sex: $X^2 = 0.75(p = 0.39)$ IQ: $t = -7.47$ (p<.0005)

UC Davis #1	36	19 (52.7%) M; 17 (47.3%) F	10.22 (2.38)	116.06 (10.69)	31	16 (51.6%) M; 15 (48.4%) F	10.86 (2.14)	73.60 (14.41)	Age: $t = 1.14$ ( $p = 0.26$ ) Sex: $X^2 = 0.01$ ( $p = 0.92$ ) IQ: $t = -13.23$ ( $p < .0005$ )
UC Davis #2	41	20 (48.8%) M; 21 (51.2%) F	11.05 (2.33)	115.16 (15.75)	46	21 (45.7%) M; 25 (54.3%) F	11.64 (2.53)	74.76 (13.83)	Age: <i>t</i> = 1.11( <i>p</i> =. 027) Sex: <i>X</i> <sup>2</sup> = 0.09 ( <i>p</i> = 0.77) IQ: <i>t</i> = -12.45 ( <i>p</i> <.0005)
Cardiff	14	6 (42.9%) M; 8 (57.1%) F	14.46 (1.79)	105.25 (9.55)	13	6 (46.2%) M; 7 (53.8%) F	16.03 (4.63)	80.92 (19.30)	Age: $t = 1.18 (p = 0.25)$ Sex: $X^2 = 0.03 (p = 0.86)$ IQ: $t = -3.91 (p = 0.001)$
Utrecht		_	_		54	38 (70.3%) M; 16 (29.7%) F	17.52 (4.22)	69.24 (7.66)	NA
Total	260	137 (52.6%) M; 123 (47.3%) F	16.55 (8.01)	111.62 (16.16)	334	181 (54.1%) M; 153 (45.8%) F	16.88 (6.43)	75.14 (12.79)	Age: $t = 0.55$ ( $p = 0.57$ ) Sex: $X^2 = 0.04$ ( $p = 0.5$ ) IQ: $t = 25.9$ ( $p = 4.0e-79$ )



PLIC = Posterior limb of internal capsule

PTR = Posterior thalamic radiation 11 EC = External/Extreme Capsule 12

18

SFO = Superior fronto-occipital fasciculus



Significant differences between 22q11.2 DS and healthy controls [Meta-analysis, FDR threshold (q < 0.05)]</li>
Significant differences between 22q11.2 DS and Healthy Controls [Mega-analysis, FDR threshold (q < 0.05)]</li>

Positive effect sizes= 22q11.2 DS > Healthy ControlsNegative effect sizes= Healthy Controls > 22q11.2 DS











CGC – AD







9e-04

7e-04

5e-04

QМ



GCC – MD











22q11DS Psychosis(+) vs. 22q11DS Psychosis(-)

Schizophrenia vs. Healthy Controls

4

0.4

0.4

0.6